School of Public Health, Ningxia Medical University, Yinchuan, Ningxia, China.
NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan, Ningxia, China.
BMC Med. 2024 Sep 4;22(1):366. doi: 10.1186/s12916-024-03586-7.
Associations of dietary sodium and potassium intake with fracture risk are inconsistent and the effects of salt substitute on fracture incidence are unknown. We assessed the effect of salt substitute compared to regular salt intake on fracture incidence using data from the Salt Substitute and Stroke Study (SSaSS).
SSaSS was a cluster-randomized controlled trial conducted in 600 villages in northern China. Villages were randomly allocated into intervention and control groups in a 1:1 ratio. Salt substitute was provided to intervention villages and control villages continued regular salt use for 5 years. The primary outcome for this secondary analysis was the incidence of all fractures. Secondary outcomes included incidence of vertebral fracture, non-vertebral fracture, and fracture of unknown or non-specific location.
20,995 participants were included in this study, and 821 fractures occurred during follow-up. Intention-to-treat analyses showed no differences between the salt substitute and regular salt groups in the incidence of all fractures (rate ratio (RR) 0.96; 95% CI 0.81 to 1.14), vertebral fracture (RR 0.82; 95% CI 0.53 to 1.26), non-vertebral fracture (RR 1.05; 95% CI 0.86 to 1.29), or fracture of unknown or non-specific location (RR 0.80; 95% CI 0.54 to 1.18).
Use of salt substitute compared to regular salt had no detectable effect on the incidence of fracture in a population at high risk of cardiovascular disease and fracture.
ClinicalTrials.gov, NCT02092090. Registered on March 12, 2014.
饮食钠和钾摄入量与骨折风险的关联并不一致,盐替代品对骨折发生率的影响也不清楚。我们使用来自盐替代与中风研究(SSaSS)的数据评估了盐替代品与常规盐摄入相比对骨折发生率的影响。
SSaSS 是在中国北方 600 个村庄进行的一项集群随机对照试验。村庄以 1:1 的比例随机分为干预组和对照组。干预组提供盐替代品,对照组继续使用常规盐 5 年。本次二次分析的主要结局是所有骨折的发生率。次要结局包括椎体骨折、非椎体骨折和未知或非特定部位骨折的发生率。
本研究共纳入 20995 名参与者,随访期间发生 821 例骨折。意向治疗分析显示,盐替代品组与常规盐组在所有骨折(发生率比(RR)0.96;95%可信区间(CI)0.81 至 1.14)、椎体骨折(RR 0.82;95%CI 0.53 至 1.26)、非椎体骨折(RR 1.05;95%CI 0.86 至 1.29)或未知或非特定部位骨折(RR 0.80;95%CI 0.54 至 1.18)的发生率方面无差异。
在心血管疾病和骨折风险高的人群中,与常规盐相比,使用盐替代品对骨折发生率没有明显影响。
ClinicalTrials.gov,NCT02092090。于 2014 年 3 月 12 日注册。